Become more familiar with the current best practices for the use of asparaginase in treating adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) through an interactive clinical scenario that includes detailed descriptions of treatment decision-making strategies.
This case focuses on the use of pediatric-inspired protocols for treating ALL in adolescents, management of treatment-related adverse events (TRAEs), as well as comparing available preparations of asparaginase.
0.75 AMA PRA Category 1 Credit(s)™
Apr 5, 2019
Apr 5, 2020
- Similarities and differences among available preparations
- Use of pediatric-inspired protocols for treating AYA patients with ALL
- Management of TRAEs in ALL
Patrick Brown, MDJohns Hopkins University School of Medicine
Baltimore, Maryland, United States
Stacy Cooper, MDJohns Hopkins University School of Medicine
Baltimore, Maryland, United States
This activity is designed to meet the educational needs of hematologists, pediatric hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with hematologic malignancies.
After successful completion of this educational activity, participants should be able to:
- Create treatment strategies that optimize the use of asparaginase for ALL
- Implement best practices to manage TRAEs associated with the use of asparaginase
This educational activity is supported by a grant from Jazz Pharmaceuticals.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 0.75 hours
To contact Postgraduate Institute for Medicine, please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Brown has disclosed that he has received consulting fees from Jazz Pharmaceuticals and Shire. He is also a member on an advisory board or review panel for Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Cooper has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
- Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney (editorial content reviewer) – no financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.